<DOC>
	<DOCNO>NCT02396069</DOCNO>
	<brief_summary>Double blind , randomize , placebo control , multiple dose , dose escalation study</brief_summary>
	<brief_title>The Evaluation Safety , Tolerability Pharmacokinetics/Pharmacodynamics JPI-289 Healthy Male Volunteers</brief_title>
	<detailed_description>A phase I clinical study , randomize , double-blind , placebo-controlled , multiple dos , dose escalation study safety , tolerability pharmacokinetics/pharmacodynamics JPI-289 healthy male volunteer .</detailed_description>
	<criteria>19~55 year healthy male BMI measurement 20kg/m²~27kg/m² 90 ≤ SBP＜140 ( mmHg ) 60 ≤ DBP＜100 ( mmHg ) 45 ≤ Pulse rate＜100 ( bpm ) Signed informed consent form participate voluntarily comply trial requirement For followup visit study period , blood sample availability History clinically significant hepatic , gastrointestinal , pulmonary , musculoskeletal , endocrine , psychiatric , hematooncologic , cardiovascular ( Specially asthma , obstructive pulmonary disease , peptic ulcer ) History skin disease graft affect absorption drug History drug abuse Positive urine drug screening Administrated investigational product previous clinical trial within 60 day screen test Donated blood within 60 day prior screen test</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>